Company CEO is featured speaker: 'Ion Channel Panels for Safety Assessment
and Drug Discovery' on Tuesday, September 9th at 2:30
CLEVELAND, Sept. 8 /PRNewswire/ -- ChanTest, the preeminent provider of validated ion channel-expressing cell lines and services for drug-discovery and development applications, will exhibit its expanding line of ion channel services and cell lines in booth 5 at the Ion Channel Targets conference in San Francisco September 9 and 10. ChanTest designed its ion channel cell lines and services to help drug-discovery researchers speed the drug-development process, save time and money, and ultimately -- to help make better, safer drugs. They are also becoming valuable new tools to help rescue shelved pharmaceutical compounds. Dr. Arthur (Buzz) Brown, ChanTest's founder and CEO, will address conference attendees in a presentation entitled, "Ion Channel Panels for Safety Assessment and Drug Discovery" on Tuesday, September 9th at 2:30.
"There are 400 genes encoding ion channels in the human genome, and
countless more ion channels can be assembled from this gene collection,"
said Dr. Brown. "Ion channels control major bodily functions, including
excitation, contraction, secretion, and fluid volume. As such, they have
become valuable primary targets for new drug therapies for hypertension,
arrhythmia, epilepsy, diabetes, and many other diseases. But too often,
drug-development researchers identify unacceptable safety risks late in the
drug-development process -- during the GLP patch-clamp studies that are
required for IND submission. When completed early in the drug-discovery
process, ChanTest's functional ion channel screens can save considerable
time, money, and other resources. We set the standard for selectivity and
safety profiling of drug candidates. Unlike most service organizations, we
validate our cell lines for testing at each phase of the drug-discovery
process. Whether you need initial high-throughput scree
Copyright©2008 PR Newswire.
All rights reserved